Ofatumumab vs. Teriflunomide in Multiple Sclerosis, Phase III Trials
Ofatumumab vs. Teriflunomide in Multiple Sclerosis, Phase III Trials
N Engl J Med. 2020 Aug 6;383(6):546-557.
Background: Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activation. The relative effects of these two drugs in patients with multiple sclerosis are not known.
Methods: In two double-blind, double-dummy, phase 3 trials, we randomly assigned patients with relapsing multiple sclerosis to receive subcutaneous ofatumumab (20 mg every 4 weeks after 20-mg loading doses at days 1, 7, and 14) or oral teriflunomide (14 mg daily) for up to 30 months. The primary end point was the annualized relapse rate. Secondary end points included disability worsening confirmed at 3 months or 6 months, disability improvement confirmed at 6 months, the number of gadolinium-enhancing lesions per T1-weighted magnetic resonance imaging (MRI) scan, the annualized rate of new or enlarging lesions on T2-weighted MRI, serum neurofilament light chain levels at month 3, and change in brain volume.
Results: Overall, 946 patients were assigned to receive ofatumumab and 936 to receive teriflunomide; the median follow-up was 1.6 years. The annualized relapse rates in the ofatumumab and teriflunomide groups were 0.11 and 0.22, respectively, in trial 1 (difference, -0.11; 95% confidence interval [CI], -0.16 to -0.06; P<0.001) and 0.10 and 0.25 in trial 2 (difference, -0.15; 95% CI, -0.20 to -0.09; P<0.001). In the pooled trials, the percentage of patients with disability worsening confirmed at 3 months was 10.9% with ofatumumab and 15.0% with teriflunomide (hazard ratio, 0.66; P = 0.002); the percentage with disability worsening confirmed at 6 months was 8.1% and 12.0%, respectively (hazard ratio, 0.68; P = 0.01); and the percentage with disability improvement confirmed at 6 months was 11.0% and 8.1% (hazard ratio, 1.35; P = 0.09). The number of gadolinium-enhancing lesions per T1-weighted MRI scan, the annualized rate of lesions on T2-weighted MRI, and serum neurofilament light chain levels, but not the change in brain volume, were in the same direction as the primary end point. Injection-related reactions occurred in 20.2% in the ofatumumab group and in 15.0% in the teriflunomide group (placebo injections). Serious infections occurred in 2.5% and 1.8% of the patients in the respective groups.
Conclusions: Among patients with multiple sclerosis, ofatumumab was associated with lower annualized relapse rates than teriflunomide. (Funded by Novartis; ASCLEPIOS I and II ClinicalTrials.gov numbers, NCT02792218 and NCT02792231.).
-
- Similar Topics
- Replies
- Views
- Last post
-
-
Ofatumumab Phase IIb Trial, MIRROR Study
by NHE » Sat Aug 22, 2020 4:05 am » in Kesimpta (Ofatumumab) - 0 Replies
- 202 Views
-
Last post by NHE
Sat Aug 22, 2020 4:05 am
-
-
- 1 Replies
- 174 Views
-
Last post by NHE
Thu Aug 20, 2020 3:32 pm
-
- 1 Replies
- 232 Views
-
Last post by NHE
Thu Aug 20, 2020 3:32 pm
-
- 4 Replies
- 1693 Views
-
Last post by zen2010
Mon Feb 25, 2019 9:52 am
-
- 0 Replies
- 301 Views
-
Last post by Petr75
Sun Oct 18, 2020 6:20 am
-
- 1 Replies
- 903 Views
-
Last post by Petr75
Sat Nov 02, 2019 9:51 am
-
- 3 Replies
- 1733 Views
-
Last post by Petr75
Thu Mar 05, 2020 9:23 am
-
- 0 Replies
- 315 Views
-
Last post by Petr75
Thu Dec 10, 2020 11:35 am
-
- 0 Replies
- 441 Views
-
Last post by Petr75
Thu Mar 19, 2020 10:24 am